{"title":"De Novo Drug Design of Potential Inhibitors of the Receptor-Binding Domain of SARS-CoV-2 Variants","authors":"E. R. Lopez","doi":"10.3390/ecb2023-14371","DOIUrl":null,"url":null,"abstract":": In this study, novel potential inhibitors of SARS-CoV-2 variants were designed de novo using generative neural networks. The top-performing ligand based on docking performance and ADMET profiles was CID #526. It forms several hydrogen bonds with wild-type SARS-CoV-2, indicating its potential as an inhibitor of the receptor-binding domain. Mutated variants of the RBD also showed good interactions with CID #526, implying the inhibitory properties of our top-performing compound against various variants. Molecular dynamics analysis showed a stable ligand–RBD complex. CID #526 can easily be synthesized using low-cost starting molecules. Overall, the generated ligands merit further investigation to determine their efficacy and safety as a treatment for COVID-19.","PeriodicalId":265361,"journal":{"name":"The 2nd International Electronic Conference on Biomedicines","volume":"79 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The 2nd International Electronic Conference on Biomedicines","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ecb2023-14371","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
: In this study, novel potential inhibitors of SARS-CoV-2 variants were designed de novo using generative neural networks. The top-performing ligand based on docking performance and ADMET profiles was CID #526. It forms several hydrogen bonds with wild-type SARS-CoV-2, indicating its potential as an inhibitor of the receptor-binding domain. Mutated variants of the RBD also showed good interactions with CID #526, implying the inhibitory properties of our top-performing compound against various variants. Molecular dynamics analysis showed a stable ligand–RBD complex. CID #526 can easily be synthesized using low-cost starting molecules. Overall, the generated ligands merit further investigation to determine their efficacy and safety as a treatment for COVID-19.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
